Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial Academic Article uri icon

Overview

MeSH Major

  • Anti-Obesity Agents
  • Cannabinoid Receptor Antagonists
  • Metabolic Syndrome X
  • Obesity
  • Overweight
  • Piperidines
  • Pyrazoles

abstract

  • In this multicenter trial, treatment with 20 mg/d of rimonabant plus diet for 2 years promoted modest but sustained reductions in weight and waist circumference and favorable changes in cardiometabolic risk factors. However, the trial was limited by a high drop-out rate and longer-term effects of the drug require further study. Clinical Trials Registration ClinicalTrials.gov Identifier: NCT00029861.

publication date

  • February 15, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1001/jama.295.7.761

PubMed ID

  • 16478899

Additional Document Info

start page

  • 761

end page

  • 75

volume

  • 295

number

  • 7